English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, June 11, 2018
アッヴィ・エーザイ・EAファーマ、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」とオート・インジェクター製剤「ヒュミラ(R)皮下注ペン」を新発売
AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA
Wednesday, June 6, 2018
エーザイとPurdue Pharma、レンボレキサントの最新データを第32回米国睡眠学会年次総会にて発表
Eisai: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting
Tuesday, June 5, 2018
エーザイとバイオジェン・インク、Elenbecestatの軽度認知障害および軽度から中等度のアルツハイマー病を対象とした臨床第II相試験の18カ月トップラインにおいて安全性と忍容性を確認
Eisai: PhaseII Clinical Study of Elenbecestat Demonstrate Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months
Monday, June 4, 2018
Eisai and Merck Announce Data at 2018 ASCO Annual Meeting
エーザイとMSD、「レンビマ(R)」と「キイトルーダ(R)」との併用療法について4がん腫に対する最新の研究成果を米国臨床腫瘍学会年次総会において発表
Thursday, May 31, 2018
U.S. FDA Designates for Priority Review of Eisai's Supplemental New Drug Application for Antiepileptic Drug Fycoma
Monday, January 9, 2023
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575